Browse Products By Molecule:

This web search service is supported by Google Inc.

Bulk Recombinant Proteins --->Targets of CAR-T Cell Therapy

Targets of CAR-T Cell Therapy  


The chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for a variety of cancers. The idea is to take out the T-cells from the patient, and genetically engineer the cells to make them express a chimeric receptor (CAR) recognizing a specific tumor-associated antigen (TAAs). As a result, the CAR-expressing T cells, when reintroduced into the patient’s body, will target and eliminate the TAA-expressing tumor cells.

Despite the early excitement, the actual path to a clinical success is not an easy one. Both Juno’s and Kite Pharma’s clinical trials ended up with unexpected and unexplained deaths caused by cerebral edema, which cast a dark shadow over the entire field.

The long-awaited breakthrough finally came this year. Kymriah, Novartis’s CAR-T therapy, was approved by FDA this August for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. This success marks a milestone in the development of targeted cell therapies, and fueled the efforts to develop / advance CAR-T treatment targeting other cancer-specific antigens. Beyond CD19, there is a growing list of targets being investigated for therapeutic intervention.

CART-LP-1.png

ACROBiosystems has developed an extensive collection of recombinant proteins to support these investigations. This growing list of proteins includes many pre-biotinylated proteins that are uniquely suitable for screening CAR-expressing cells. In addition, we also supply hard-to-make proteins such as BCMA, ROR1, and EGFRVIII.

Promotion & Policy

All small packs of proteins of CAR-T cell targets are open to offer free sample now.

You can simply find proteins of your interest at the table below. Please fill out the online Free Sample Application Form, or directly send email to order@acrobiosystems.com to request.

Policy

  • Shipping Fee: ACROBiosystems will charge a $45 shipping fee for sample delivery, or the customer authorize ACROBiosystems to use her/his own courier account.
  • Limit: Each customer can request only 1 small pack and sample feedback should be given within 1 month as soon as you
    receive it.
  • This offer is valid through October 31st, 2017.
  • Other restrictions may apply.

Recommended Products

Targets Diseases Recommended Products
BCMA Multiple myeloma, leukemia, B-Cell lymphoma BC7-H82F0 (Biotinylated Human BCMA)
BCA-H522Y (Human BCMA)
ROR1 Leukemia, breast cancer RO1-H821y (Biotinylated Human ROR1)
RO1-H522y (Human ROR1)
CD33 Acute myeloid leukemia CD3-H82E7 (Biotinylated Human CD33)
CD3-H5226 (Human CD33)
EGFRVIII Glioblastoma EGR-H82E0 (Biotinylated Human EGFRVIII)
EGI-H52H4 (Human EGFRvIII)
CD30 Leukemia, B-Cell lymphoma CD0-H82E6 (Biotinylated Human CD30)
CD0-H5229 (Human CD30)
EGFR NSCLC, epithelial carcinoma, glioma EGR-H82E3 (Biotinylated Human EGFR)
EGR-H5222 (Human EGFR)
FOLR1 Ovarian cancer FO1-M82E9 (Biotinylated Mouse FOLR1)
FO1-H5229 (Human FOLR1)
HER2 Ovarian cancer, breast cancer, glioblastoma, osteosarcoma HE2-H822R (Biotinylated Human Her2)
HE2-H5225 (Human Her2)
c-MET/HGFR Malignant melanoma, breast cancer MET-H82E1 (Biotinylated Human HGF R)
MET-H5227 (Human HGF R)
CAIX Renal cell carcinoma (RCC) CA9-H5226(Human CA9 (38-414))
CD19 Acute leukemia, B-Cell lymphoma CD9-H8259 (Biotinylated Human CD19)
CD20 Leukemia, B-Cell lymphoma CD0-H5268 (Human MS4A1 / CD20, Fc Tag)
CD22 Leukemia, B-Cell lymphoma SI2-H5228 (Human Siglec-2 / CD22)
EpCAM Liver neoplasms, stomach neoplasms EPM-H82E8 (Biotinylated Human EpCAM)
EPM-H5223 (Human EpCAM)
GPC3 Hepatocellular carcinoma GP3-H5223 (Human Glypican 3)
IL13Rα2 Glioma IL2-H5257 (Human IL13Rα2, Fc Tag)
MSLN Mesothelioma, ovarian cancer MSN-H82E9 (Biotinylated Human MSLN)
MSN-H5223 (Human MSLN)
MUC1 Seminal vesicle cancer MU1-H5252 (Human MUC-1, Fc Tag)
CD138 Multiple myeloma SD1-H5228 (Human Syndecan-1 / CD138)
CD38 B-cell Malignancies CD8-H82E7 (Biotinylated Human CD38)
CD8-H5224 (Human CD38)

Case study: evaluation of CD19 CAR expression

  1. The following case was described in a recent paper by MacLeod DT, et al. published on Jounal of Molecular therapy. The detailed infomation can be found at MacLeod DT, et al., 2017, Mol Ther. 25(4):949-961.doi: 10.1016/j.ymthe.2017.02.005.
  2. Method: Flow Cytometry
  3. Equipment: BD Fortessa flow cytometer (BD Biosciences)
  4. Reagents: Biotinylated CD19-Fc (Cat. No. CD9-H8259, ACROBiosystems); streptavidin-PE and anti-CD3-BV711 (BioLegend);
  5. Samples: TRC1-2-treated, AAV:TRAC:CAR-transduced T cells
  6. Brief protocol: For evaluation of CAR expression, cells were stained with biotinylated CD19-Fc (Cat. No. CD9-H8259, ACROBiosystems) for 15 min at room temperature. Cells were thoroughly washed before staining with antibodies for additional surface markers. Streptavidin-PE and anti-CD3-BV711 were used to stain surface antigens. Cell Trace Violet (Thermo Fisher Scientific) was used at a concentration of 1 mM to label cells for 10 min. All FACS data was analyzed using FlowJo software.
  7. Results: Analysis of CD3 and CAR expression by flow cytometry showed a high frequency of CD19 CAR+ cells in the CD3- population. (More details can be found at MacLeod DT, et al., 2017, Mol Ther. 25(4):949-961.doi: 10.1016/j.ymthe.2017.02.005.)
  8. CAR-expression.png

    Figure A. Activated T cells were electroporated with TRC1-2 mRNA and transduced with AAV:TRAC:CAR at an MOI of 400,000 vg/cell and cultured for 5 days in the presence of IL-2. Five days post-transduction, cells were stained for expression of the CAR using a biotinylated CD19-Fc reagent and CD3, with TRC1-2-treated, mock-transduced cells used as a control for gating of CAR expression. CD3+ cells were then depleted. Enriched CD3 cells were cultured for 3 additional days in the presence of IL-15 and IL-21 and then analyzed again by flow cytometry for CD3 and CAR expression.